Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
ABT US​

Abbott Laboratories(ABT US)

$103.70+1.191.16%Ext:$98.11-5.595.39%(Market Closed · 00:00:05 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Abbott Laboratories — Company Profile

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Robert Ford
Headquarters
Abbott Park, IL, US
IPO Date
Mar 17, 1980
Employees
115,000
Website
www.abbott.com

Key Metrics

Price
$97.50
Market Cap
$168.71B
Revenue (TTM)
$12.59B
Net Income (TTM)
$928.00M
EPS (TTM)
0.53
P/E (TTM)
26.88
P/B (TTM)
3.24
Dividend Yield
2.40%
ROE (TTM)
2.07%
ROA (TTM)
0.98%
Operating Margin
16.50%
Beta
0.18

Dividends

Last Dividend
$0.63
Last Yield
0.02%

Summary

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Website
www.abbott.com
Location
Abbott Park, IL, US
Phone224 667 6100
Employees115,000
CEORobert Ford
Sector
Health Care
Industry
Pharmaceuticals
IPO DateMar 17, 1980

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(3.6K)

Expand
  • 8-KOther Events21 Oct
  • 8-KResults of Operations and Financial Condition21 Oct
  • 4Stratton John G2 Oct
  • 4Gonzalez Patricia Paola2 Oct
  • 4Conroy Kevin T2 Oct
  • 4Ahuja Nita2 Oct
  • 4Roman Michael F2 Oct
  • 4Conroy Kevin T25 Sep
  • 4MCCOY JOHN A. JR.3 Sep
  • 4Boudreau Philip P3 Sep
  • 144MCCOY JOHN A. JR.2 Sep
  • 4Ford Robert B27 Aug
  • 144Ford Robert B25 Aug
  • 8-KRegulation FD Disclosure20 Aug
  • 4Morrone Louis H.13 Aug
  • 144Morrone Louis H.11 Aug
  • 10-QQ2ended 30 Jun 202628 Jul
  • 8-KResults of Operations and Financial Condition16 Jul
  • 4Stratton John G1 Jul
  • 4Roman Michael F1 Jul

EDINET Filings(20)

Expand
  • IRExtraordinary Report30 Jul 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)30 Apr 2025
  • IRExtraordinary Report27 Feb 2025
  • PRSSecurities registration statement15 Dec 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)26 Sep 2024
  • IRExtraordinary Report22 Aug 2024
  • PRSSecurities registration statement13 Jun 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)26 Apr 2024
  • IRExtraordinary Report22 Feb 2024
  • PRSSecurities registration statement14 Dec 2023
  • 10-KAnnual Securities Report (2021.01.01-2021.12.31)27 Apr 2022
  • PRSSecurities registration statement9 Dec 2021
  • PRSSecurities registration statement11 Jun 2021
  • 10-KAnnual Securities Report (2020.01.01-2020.12.31)30 Apr 2021
  • PRSSecurities registration statement22 Dec 2020
  • 10-KAnnual Securities Report (2019.01.01-2019.12.31)29 Apr 2020
  • 10-KAnnual Securities Report (2018.01.01-2018.12.31)25 Apr 2019
  • 10-KAnnual Securities Report (2017.01.01-2017.12.31)27 Apr 2018
  • 10-KAnnual Securities Report (2016.01.01-2016.12.31)28 Apr 2017
  • 10-KAnnual Securities Report (2015.01.01-2015.01.31)27 Apr 2016

News

  • The Dividend Aristocrats Ranked By Quality Scores (October 2026)23 Oct
  • Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer23 Oct
  • Abbott Laboratories $ABT Shares Sold by Axxcess Wealth Management LLC23 Oct
  • Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook22 Oct
  • Cologuard Is Working—So Why Isn't Abbott Stock?22 Oct
  • Abbott: 3 Key Takeaways for Long-Term Investors21 Oct
  • Abbott Q3: Nutrition Spin-Out, Narrowed Guidance Rocks Stock; For Now, At Least21 Oct
  • Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm21 Oct
  • Abbott Laboratories (ABT) Q3 2026 Earnings Call Transcript21 Oct
  • Abbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition Business Spin-Off21 Oct
  • What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call21 Oct
  • ABT Stock Down Post Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up21 Oct
  • Abbott (ABT) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates21 Oct
  • Abbott (ABT) Misses Q3 Earnings Estimates21 Oct
  • Abbott to Carve Out Nutrition Business Into Independent Company21 Oct
  • Abbott lowers 2026 sales growth forecast on medical device weakness21 Oct
  • Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance21 Oct
  • Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company21 Oct
  • How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings20 Oct
  • 2 Industries Beyond AI With Long-Term Demand Drivers for 202719 Oct

Mentions in Filings

  • … ion is also home to more than 400 major corporate headquarters, including over 30 in the Fortune 500. The largest of such companies include Archer Daniels Midland, Deere, Allstate, AbbVie, United Airlines Holdings, <strong>Abbott Laboratories</strong>, Mondelez International, US Foods Holding Corp., Kraft Heinz, McDonald’s and Exelon. The Chicago area is also home to a number of the nation’s leading research universities, including the University of Chicago, Nort …
    MFB Bancorp, Inc.Abbott Laboratories·S-1/A - Registration statement (general form, amendment)·Q4 26·23 Oct
  • … , as Chief Medical Officer, Vice President and Head of Clinical Science at Theravance Biopharma US, Inc., a biopharmaceutical company. Dr. Lee previously held positions at Genentech, Inc., Eli Lilly and Company and <strong>Abbott Laboratories</strong> (now AbbVie Inc.) and served as a faculty member at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received a B.S. in Biology and an M.D. from the University of Nort …
    Lycia Therapeutics, Inc.Abbott Laboratories·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·23 Oct
  • … ficer and a director of Facet Biotech Corporation, a publicly-held biology driven antibody company with a focus in multiple sclerosis and oncology. He held that position from 2008 until the company’s acquisition by <strong>Abbott Laboratories</strong> in 2010. Previously, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. (PDL BioPharma), a publicly-held biopharmaceutical company, from 2008 until Facet Biotech was spun off fr …
    Aspen Neuroscience, Inc.Abbott Laboratories·S-1/A - Registration statement (general form, amendment)·Q4 26·22 Oct
  • … om March 2011 to June 2013. He previously served as the Chief Financial Officer for Apartments.com, a Classified Ventures Company from 2006 to 2011. Mr. Thakker also held leadership roles in financial management at <strong>Abbott Laboratories</strong> and Baxter International Inc. Mr. Thakker received an M.B.A. from Northwestern University’s Kellogg School of Management and is an accredited certified public accountant (inactive). As the Chairman, President and C …
    GIFTIFY, INC.Abbott Laboratories·DEF 14A - Definitive proxy statement·Q4 26·20 Oct
  • … uding one with the largest cancer center in Singapore, the National Cancer Centre Singapore (“NCCS”), a Hong Kong listed pharmaceutical company, Jacobson, a U.S. manufacturer of in-vitro diagnostic medical devices, <strong>Abbott Laboratories</strong> (“Abbott”), and Effibar, an India based company focused on a variety of industries with extensive experience dealing with governmental authorities. We plan to carry out our global sales strategy through research col …
    Mountain Crest Acquisition Corp. VAbbott Laboratories·DEFM14A - Definitive proxy statement (merger)·Q4 26·20 Oct
  • … uding one with the largest cancer center in Singapore, the National Cancer Centre Singapore (“NCCS”), a Hong Kong listed pharmaceutical company, Jacobson, a U.S. manufacturer of in-vitro diagnostic medical devices, <strong>Abbott Laboratories</strong> (“Abbott”), and Effibar, an India based company focused on a variety of industries with extensive experience dealing with governmental authorities. We plan to carry out our global sales strategy through research col …
    Cubebio Co., LtdAbbott Laboratories·424B3 - Prospectus filing (Rule 424(b)(3))·20 Oct·20 Oct

Key Stats

Trading

Px/Chg 1D$97.50 / +0.84%
Prev Close$108.33
% of 52Wk H76.75%
Avg Volume12.46M
Beta0.18
Mkt Cap168.71B
FD Mkt Cap182.59B

Float

Shrs Out/Float1.73B / 1.72B
Short Float0.01%
Days to Cover1.48
Stock Repurchased$180.00M

Current Valuation

EV196.60B
EV/EBITDA17.54
EV/Sales4.36
P/B3.24
P/S3.74
FCF Yield0.54%
ROE2.07%
ROA0.98%
Current Ratio1.39

Dividend

Cash$0.63
Yield2.40%
Yield (TTM)2.40%

Estimates

P/E26.88
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings70.6328.2632.2116.8692.33183.50
Price / Sales8.464.494.605.3914.3113.52
Price / Book Value4.255.344.774.743.153.27
Price / Free Cash Flow69.0925.1036.4335.5862.44185.90
ENTERPRISE VALUE METRICS
Enterprise Value200,185.5204,198.3193,516.0233,882.6171,159.4198,171.0
Enterprise Value / Sales9.154.684.825.5814.9415.74
Enterprise Value / EBITDA45.7717.1818.2521.5960.65111.21
Enterprise Value / EBIT52.6423.6926.2930.7171.32111.21

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue71.9%43,075.043,653.040,109.041,950.044,328.0
Gross Income1.5%23,214.022,323.020,037.021,325.024,607.0
EBITDA-1.3%12,159.011,888.010,605.010,834.011,553.0
EBIT53.5%8,621.08,621.07,362.07,616.08,807.0
Net Income-2%7,071.06,933.05,723.013,402.06,524.0
EPS (Diluted)-1.4%3.943.913.277.643.72
BALANCE SHEET
Cash & ST Inv-3.4%10,249.010,170.07,279.07,967.08,939.0
Total Assets3.6%75,196.074,438.073,214.081,414.086,713.0
Total Liabilities-3.5%39,172.037,533.034,387.033,513.033,942.0
Total Shareholder Equity9.8%35,802.036,686.038,603.047,664.052,130.0
CASH FLOW
Net Operating Cash Flow-2.4%10,533.09,581.07,261.08,558.09,566.0
Cap Ex3.6%-1,885.0-1,777.0-2,202.0-2,207.0-2,171.0
Free Cash Flow-3.8%8,648.07,804.05,059.06,351.07,395.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)103.70
Basic Shares1,730.38
Market Cap179,440.8
Diluted Shares1,738.00
Fully Diluted Shares Outstanding1,738.00
Fully Diluted Market Cap180,230.6
+Consolidated Debt34,047.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-6,803.0
−Short-term Investments-492.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest640.0
+Pension Liabilities—
Enterprise Value207,324.8

Segment data

Revenue

by Products and services

  • Medical Devices48%
  • Diagnostic Products20%
  • Nutritional Products19%
  • Established Pharmaceutical Products12%

Revenue

by Geography

  • United States40%
  • Non-us37%
  • D [e]6%
  • C [n]4%
  • I [n]4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US